Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.

Bristol Myers Squibb (NYSE:BMY) has tapped Cristian Massacesi, as executive vice president, chief medical officer, and head of development, effective August 1, 2025. Massacesi most recently served as ...

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...

The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb is making progress paying down debt from prior deals and improving financial flexibility so it can make ...

The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...